A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel
A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis
What it found
We found no results in the registry or in papers.
What was tested
Compared with
- Simvastatin
HMG-CoA reductase inhibitor
What it measured
Main measures
First documented relapse
Relapses
Who could take part
Relapsing MS
Show the full criteria
Inclusion criteria
Inclusion: • The patient must give written informed consent prior to any study related activities. Study related activities are any procedures that would not have been performed during normal management of the patient. Exclusion: • Any condition that might give rise to similar symptoms as MS.
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
• The time to first documented relapse.
Loading reviews and guidelines…
History
Started
Nov 2005